Text Size A A

E-Mail to a Friend

secret  Click to Play Audio

Dr. Oliver Press at ASH 2012

Dr. Oliver Press at ASH 2012

In this interview from the 2012 American Society of Hematology (ASH) Annual Meeting Dr. Oliver Press explains why there is excitement around antibody-drug conjugates (ADC). ADC allows doctors to selectively focus the drug on the cancer cells reducing the amount of drugs required overall. It is a targeted therapy that should cause a better response in the tumor and minimize toxicity for the patient. Within the last few years, chemists have come up with linkers that keep the drug on antibody until they are delivered to the cancer cell. The first successful ADC for lymphoma was brentuximab vedotin, which is now FDA approved and works well with patients who have relapsed with Hodgkin's lymphoma or T-cell lymphoma. Antibody-drug conjugates are now available in the treatment of B-cell lymphoma. It provides a new targeted approach, a more convenient infusion, and reduced side effects.

Related Videos

Dr. Ajay Gopal at ASH 2011

In this interview from the 2011 American Society of Hematology (ASH) Annual Meeting Dr. Ajay Gopal tells how Hodgkin's lymphoma presents and gives his perspective on finding a specialist. He explains how he determines the stage of the disease by looking at factors such as disease location, white blood cell count, age of the patient and even gender. Dr. Gopal describes the course of therapy from the first meeting with the patient, doing testing and blood work to diagnosis disease, and creating a treatment regimen that strikes the right balance for the patient.

Dr. Ajay Gopal at ASH 2012

In this interview from the 2012 American Society of Hematology (ASH) Annual Meeting Dr. Ajay Gopal, discusses a new study which looks into whether radio immunotherapy could be an improvement for patients with advanced lymphomas. He has pursued an approach to deliver targeted radiation by attaching a radioactive isotope to a monoclonal antibody which specifically targets B-cell lymphomas. They have escalated the dose to the maximum safe dose to deliver more radiation to the tumor sites. The trial replaced a standard high dose therapy regimen with target radiation using radio immunotherapy. Dr. Gopal shares the results of the study.

Dr. Oliver Press

Dr. Oliver Press is a medical oncologist who specializes in treating patients with lymphoma, leukemia, and myeloma. In this video Dr. Press describes some of the new and exciting treatments that are becoming available for patients with lymphoma. Because there because there are 67 varieties of lymphoma, establishing the correct diagnosis at the start is important. At SCCA, the reason we are curing more patients and have better survival rates for patients with lymphoma is because of clinical research. It is very rewarding to watch new discoveries go from cell lines, to mouse models and into people and then become therapies that are very curative for patients with lymphoma.